The use of ketamine as an antidepressant: A systematic review and meta-analysis

Human Psychopharmacology

Volumn 30, Issue 3, 2015, Pages 152-163

  Coyle, Caoimhe M ^a   Laws, Keith R ^a  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

bipolar disorder; depression; ketamine; major depressive disorder

Indexed keywords

ANTIDEPRESSANT AGENT; KETAMINE; AMINO ACID RECEPTOR BLOCKING AGENT;

ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; DRUG EFFECT; EFFECT SIZE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX RATIO; SYSTEMATIC REVIEW; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; SEX DIFFERENCE; TIME;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; SEX FACTORS; TIME FACTORS;

EID: 84928105933     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2475     Document Type: Review

References (51)

1. aan het Rot M, Collins KA, Murrough JW, et al,. 2010. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67 (2): 139-145. doi: 10.1016/j.biopsych.2009.08.038
2. aan het Rot M, Zarate CA, Jr., Charney DS, Mathew SJ,. 2012. Ketamine for depression: where do we go from here? Biol Psychiatry 72 (7): 537-547. doi: 10.1016/j.biopsych.2012.05.003
3. Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R,. 2012. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. Journal of ECT 28 (3): 157-161. doi: 10.1097/YCT.0b013e31824f8296
4. Begg CB, Mazumdar M,. 1994. Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
5. Berman RM, Cappiello A, Anand A, et al,. 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47 (4): 351-354. doi: 10.1016/s0006-3223(99)00230-9
6. Carlson PJ, Diazgranados N, Nugent AC, et al,. 2013. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry 73 (12): 1213-1221. doi: 10.1016/j.biopsych.2013.02.008
7. Carrier N, Kabbaj M,. 2013. Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology 70 (0): 27-34. doi: 10.1016/j.neuropharm.2012.12.009
8. Cornwell BR, Salvadore G, Furey M, et al,. (2012). Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biological Psychiatry 72: 555-561.
9. Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV,. 2014. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend 136: 153-157.
10. Diazgranados N, Ibrahim L, Brutsche NE, et al,. 2010a. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67 (8): 793-802. doi: 10.1001/archgenpsychiatry.2010.90
11. Diazgranados N, Ibrahim LA, Brutsche NE, et al,. 2010b. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71 (12): 1605-1611. doi: 10.4088/JCP.09m05327blu
12. Duncan WC Jr., Selter J, Brutsche N, et al,. (2013). Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. Journal of Affective Disorders 145: 115-119.
13. Duval S, Tweedie R,. 2000. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455-463.
14. Egger M, Davey Smith G, Schneider M, Minder C,. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
15. Freeman TP, Morgan CJA, Pepper F, Howes OD, Stone JM, Curran HV,. 2013. Associative blocking to reward-predicting cues is attenuated in ketamine users but can be modulated by images associated with drug use. Psychopharmacology (Berl) 225 (1): 41-50. doi: 10.1007/s00213-012-2791-0
16. Higgins JPT, Green S, (eds). 2011. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration. (http://www.cochrane.org/training/cochrane-handbook).
17. Hillemacher T, Bleich S, Demling J, Kornhuber J,. 2007. Ketamine for the treatment of depression: what about the addictive potential? Australian and New Zealand Journal of Psychiatry 41 (9): 772-773.
18. Ibrahim L, Diazgranados N, Franco-Chaves J, et al,. 2012. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37 (6): 1526-1533. doi: 10.1038/npp.2011.338
19. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al,. 2011. Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 35 (4): 1155-1159. doi: 10.1016/j.pnpbp.2011.03.019
20. Kollmar R, Markovic K, Thurauf N, Schmitt H, Kornhuber J,. 2008. Ketamine followed by memantine for the treatment of major depression. Australian and New Zealand Journal of Psychiatry 42 (2): 170-170.
21. Lapidus KAB, Levitch CF, Perez AM, et al,. 2014. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry (In press). doi: 10.1016/j.biopsych.2014.03.026
22. Larkin GL, Beautrais AL,. 2011. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. International Journal of Neuropsychopharmacology 14 (8): 1127-1131. doi: 10.1017/s1461145711000629
23. Larkin GL, Beautrais AL, Turelli RR, et al,. 2011. P03-437-a preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Eur Psychiatry 26: Supplement 1 (0): 1607. doi: 10.1016/S0924-9338(11)73311-9
24. Liebrenz M, Borgeat A, Leisinger R, Stohler R,. 2007. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med Wkly 137 (15-16): 234-236.
25. Liebrenz M, Stohler R, Borgeat A,. 2009. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World Journal of Biological Psychiatry 10 (4): 640-643. doi: 10.3109/15622970701420481
26. Loo CK, Katalinic N, Garfield JBB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R,. 2012. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord 142 (1-3): 233-240. doi: 10.1016/j.jad.2012.04.032
27. Luckenbaugh DA, Ibrahim L, Brutsche N, et al,. 2012. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord 14 (8): 880-887. doi: 10.1111/bdi.12003
28. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS,. 2010. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. International Journal of Neuropsychopharmacology 13 (1): 71-82. doi: 10.1017/s1461145709000169
29. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P,. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62 (10): 1006-1012. doi: 10.1016/j.jclinepi.2009.06.005
30. Morgan CJA, Curran HV, Iscd. 2012. Ketamine use: a review. Addiction 107 (1): 27-38. doi: 10.1111/j.1360-0443.2011.03576.x
31. Morgan CJA, Muetzelfeldt L, Curran HV,. 2010. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 105 (4): 766-766. doi: 10.1111/j.1360-0443.2009.02761.x
32. Murrough JW, Perez AM, Pillemer S, et al,. 2012. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74 (4): 250-256. doi: 10.1016/j.biopsych.2012.06.022
33. Murrough JW, Iosifescu DV, Chang LC, et al,. 2013. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170: 1134-1142.
34. Niciu MJ, Grunschel BDG, Corlett PR, Pittenger C, Bloch, MH,. 2013. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J Psychopharmacol 27 (7): 651-654. doi: 10.1177/0269881113486718
35. Permoda-Osip A, Adamski R, Bartkowska-Sniatkowska A, Chlopocka-Wozniak M, Skibinska M, Rybakowski JK,. 2011. Efficacy of single ketamine infusion in bipolar depression: relationship with serum BDNF. Eur Neuropsychopharmacol 21: S428-S429.
36. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA, Jr., 2009. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 65 (2): 181-184. doi: 10.1016/j.biopsych.2008.09.029
37. Price RB, Nock MK, Charney DS, Mathew SJ,. 2009. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66 (5): 522-526. doi: 10.1016/j.biopsych.2009.04.029
38. Price, RB, Iosifescu DV, Murrough JW, et al,. 2014. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 31 (4): 335-343.
39. Rasmussen KG, Lineberry TW, Galardy CW, et al,. 2013. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 27 (5): 444-450. doi: 10.1177/0269881113478283
40. Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A,. 2013. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Human Psychopharmacology-Clinical and Experimental 28 (1): 87-90. doi: 10.1002/hup.2271
41. Salvadore G, Cornwell BR, Colon-Rosario V, et al,. 2009. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 65 (4): 289-295. doi: 10.1016/j.biopsych.2008.08.014
42. Salvadore G, Cornwell BR, Sambataro F, et al,. 2010. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35 (7): 1415-1422. doi: 10.1038/npp.2010.24
43. Salvadore G, Singh JB,. 2013. Ketamine as a fast acting antidepressant: current knowledge and open questions. CNS Neuroscience and Therapeutics 19 (6): 428-436. doi: 10.1111/cns.12103
44. Salvadore G, van der Veen JW, Zhang Y, et al,. 2012. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. International Journal of Neuro psychopharmacology 15 (8): 1063-1072. doi: 10.1017/s1461145711001593
45. Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T,. 2013. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 34 (4): 287-293
46. Thakurta RG, Ray P, Kanji D, Das R, Bisui B, Singh OP,. 2012. Rapid antidepressant response with ketamine: is it the solution to resistant depression. Indian J Psychol Med 34 (1): 56-60. doi: 10.4103/0253-7176.96161
47. Trujillo KA, Zamora JJ, Warmoth KP,. 2008. Increased response to ketamine following treatment at long intervals: implications for intermittent use. Biol Psychiatry 63 (2): 178-183. doi: 10.1016/j.biopsych.2007.02.014
48. Young SN,. 2013. Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin. J Psychiatry Neurosci 38 (2): 78-83. doi: 10.1503/jpn.120128
49. Zarate CA, Jr., Brutsche NE, Ibrahim L, et al,. 2012a. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71 (11): 939-946. doi: 10.1016/j.biopsych.2011.12.010
50. Zarate CA, Jr., Brutsche N, Laje G, et al,. 2012b. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72 (4): 331-338. doi: 10.1016/j.biopsych.2012.03.004
51. Zarate CA, Jr., Singh JB, Carlson PJ, et al,. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63 (8): 856-864. doi: 10.1001/archpsyc.63.8.856